SAFETY, PHARMACOKINETICS, AND ACTIVITY OF THE ANTI-NAPI2B ANTIBODY-DRUG CONJUGATE DNIB0600A: A PHASE I STUDY IN PATIENTS WITH NON-SMALL CELL LUNG CANCER AND PLATINUM-RESISTANT OVARIAN CANCER

被引：0
|
作者：
Gerber, David [1 ]
Infante, Jeffrey [2 ]
Gordon, Michael [3 ]
Schiller, Joan [1 ]
Spigel, David [4 ]
Wang, Yulei [5 ]
Shames, David S. [5 ]
Choi, Younjeong [5 ]
Kahn, Robb [5 ]
Xu, Jian [5 ]
Lin, Kedan [5 ]
Wood, Katie [5 ]
Maslyar, Daniel [5 ]
Burris, Howard [4 ]
机构：
[1] UT Southwestern Med Ctr, Harold C Simmons Canc Ctr, Dallas, TX USA
[2] Tennessee Oncol Pllc, Sarah Cannon Res Inst, Nashville, TN USA
[3] Pinnacle Oncol Hematol, Scottsdale, AZ USA
[4] Sarah Cannon Res Inst, Nashville, TN USA
[5] Genentech Inc, San Francisco, CA USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2013年 / 8卷
关键词：
NSCLC; ADC; Phase I; NaPi2b;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P3.11-014
引用
收藏
页码：S1190 / S1191
页数：2
相关论文
共 50 条
  • [31] JS']JSKN003, a HER2-targeting antibody-drug conjugate, in patients with platinum-resistant ovarian cancer: A pooled analysis of two studies
    Rao, Q.
    Chen, Y.
    Gao, B.
    Weng, G.
    Zhang, Z.
    Wilkinson, K.
    Liu, J.
    Shu, Y.
    Liu, L.
    Lan, C.
    Park, J. J. W.
    Lin, A.
    Wang, X.
    ANNALS OF ONCOLOGY, 2024, 35 : S575 - S576
  • [32] Enapotamab vedotin, an AXL-specific antibody-drug conjugate, shows preclinical antitumor activity in non-small cell lung cancer
    Koopman, Louise A.
    Terp, Mikkel G.
    Zom, Gijs G.
    Janmaat, Maarten L.
    Jacobsen, Kirstine
    Gresnigt-van den Heuve, Elke
    Brandhorst, Marcel
    Forssmann, Ulf
    de Bree, Freddy
    Pencheva, Nora
    Lingnau, Andreas
    Zipeto, Maria A.
    Parren, Paul W. H., I
    Breij, Esther C. W.
    Ditzels, Henrik J.
    JCI INSIGHT, 2019, 4 (21)
  • [33] An AXL-specific antibody-drug conjugate shows preclinical anti-tumor activity in non-small cell lung cancer, including EGFR-inhibitor resistant NSCLC
    Koopman, Louise A.
    Janmaat, Maarten L.
    Jacobsen, Kirstine
    Terp, Mikkel Green
    Gresnigt-van den Heuvel, Elke
    Forssman, Ulf
    Lingnau, Andreas
    Parren, Paul W.
    Ditzel, Henrik
    Breij, Esther C.
    CANCER RESEARCH, 2018, 78 (13)
  • [34] A Phase I Study of the Safety and Pharmacokinetics of Higher-Dose Icotinib in Patients With Advanced Non-Small Cell Lung Cancer
    Liu, Jian
    Wu, Lihua
    Wu, Guolan
    Hu, Xingjiang
    Zhou, Huili
    Chen, Junchun
    Zhu, Meixiang
    Xu, Wei
    Tan, Fenlai
    Ding, Lieming
    Wang, Yinxiang
    Shentu, Jianzhong
    ONCOLOGIST, 2016, 21 (11): : 1294 - 1295
  • [35] Phase Ib study of cofetuzumab pelidotin, an anti-PTK7 antibody-drug conjugate, in patients with PTK7-expressing recurrent non-small cell lung cancer (rNSCLC)
    Cho, B. C.
    Johnson, M. L.
    Bar, J.
    Schaefer, E.
    Yoh, K.
    Zer, A.
    Moskovitz, M. T.
    Lee, S-H.
    Moreno Garcia, V.
    De Miguel Luken, M. J.
    Okuma, Y.
    Kim, J-H.
    Lee, C-H.
    Ansell, P. J.
    de Almeida, C. Biesdorf
    Saab, R.
    Freise, K.
    Ramies, D.
    Jeng, E.
    Camidge, D. R.
    ANNALS OF ONCOLOGY, 2023, 34 : S460 - S461
  • [36] Phase I study of ABBV-399, a c-Met antibody-drug conjugate (ADC), as monotherapy and in combination with erlotinib in patients (pts) with non-small cell lung cancer (NSCLC).
    Angevin, Eric
    Strickler, John H.
    Weekes, Colin D.
    Heist, Rebecca Suk
    Morgensztern, Daniel
    Nemunaitis, John J.
    Fan, Xiaolin
    Beaulieu, Juliette
    Motwani, Monica
    Afar, Daniel E.
    Naumovski, Louie
    Kelly, Karen
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [37] Phase ib study of safety, tolerability and pharmacokinetics of simotinib in patients with advanced non-small cell lung cancer
    Hu, Xingsheng
    Han, Xiaohong
    Zhang, Li
    Ding, Yanhua
    Wang, Hanping
    Mu, Hua
    Sun, Yan
    Shi, Yuankai
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [38] Initial safety and activity findings froma phase IB escalation study of mirvetuximab soravtansine, a folate receptor alpha (FRa-targeting antibody-drug conjugate (ADC), with pembrolizumab in platinum-resistant epithelial ovarian cancer (EOC) patients
    Matulonis, U. A.
    Moore, K. N.
    Martin, L. P.
    Vergote, I. B.
    Castro, C. M.
    Gilbert, L.
    Berkenblit, A.
    Birrer, M. J.
    O'Malley, D. M.
    GYNECOLOGIC ONCOLOGY, 2018, 149 : 38 - 38
  • [39] Targeting MUC16 with the THIOMAB™-drug conjugate DMUC4064A in patients with platinum-resistant ovarian cancer: A phase I expansion study
    Moore, Kathleen
    Hamilton, Erica P.
    Burris, Howard A.
    Barroilhet, Lisa M.
    Gutierrez, Martin
    Wang, Judy S.
    Patel, Manish R.
    Birrer, Michael J.
    Flanagan, W. Mike
    Wang, Yulei
    Garg, Amit
    Lu, Xuyang
    Vaze, Anjali
    Amin, Dilip
    Leipold, Douglas
    Commerford, S. Renee
    Humke, Eric W.
    Liu, Joyce F.
    CANCER RESEARCH, 2018, 78 (13)
  • [40] Targeting MUC16 with the THIOMAB™-drug conjugate DMUC4064A in patients with platinum-resistant ovarian cancer: a Phase I escalation study
    Liu, Joyce F.
    Moore, Kathleen N.
    Wang, Judy S.
    Patel, Manish
    Birrer, Michael J.
    Hamilton, Erika
    Barroilhet, Lisa
    Flanagan, William M.
    Wang, Yulei
    Garg, Amit
    Lu, Xuyang
    Vaze, Anjali
    Amin, Dilip
    Leipold, Doug
    Commerford, S. Renee
    Humke, Eric W.
    Burris, Harold A.
    CANCER RESEARCH, 2017, 77
12345